Utilization and cost of sildenafil in a large managed care organization with a quantity limit on sildenafil.

Journal of managed care pharmacy : JMCP

Volumn 11, Issue 8, 2005, Pages 674-680

  Cooke, Catherine E ^a   Wong, Winston ^a   Lee, Helen ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHODIESTERASE INHIBITOR; PIPERAZINE DERIVATIVE; SILDENAFIL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; COST CONTROL; DRUG COST; DRUG UTILIZATION; ECONOMICS; HEALTH INSURANCE; HUMAN; IMPOTENCE; INSURANCE; MALE; METHODOLOGY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; ORGANIZATION AND MANAGEMENT; PRESCRIPTION; RISK FACTOR; STANDARD; STATISTICS; TIME;

ADMINISTRATION, ORAL; ADULT; AGED; CARDIOVASCULAR DISEASES; COST CONTROL; DRUG COSTS; DRUG UTILIZATION; HUMANS; IMPOTENCE; INSURANCE CLAIM REVIEW; INSURANCE, PHARMACEUTICAL SERVICES; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PRESCRIPTIONS, DRUG; RISK FACTORS; TIME FACTORS;

EID: 33646080071     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2005.11.8.674     Document Type: Article

References (0)